BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35961779)

  • 61. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
    Zedan HT; Smatti MK; Al-Sadeq DW; Al Khatib HA; Nicolai E; Pieri M; Bernardini S; Hssain AA; Taleb S; Qotba H; Issa K; Abu Raddad LJ; Althani AA; Nasrallah GK; Yassine HM
    J Med Virol; 2024 Mar; 96(3):e29527. PubMed ID: 38511514
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
    PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
    Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
    Front Immunol; 2021; 12():727850. PubMed ID: 34671350
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
    Sidler D; Born A; Schietzel S; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Seyed Jafari SM; Radonjic-Hoesli S; Chan A; Hoepner R; Bacher U; Mani LY; Iype JM; Suter-Riniker F; Staehelin C; Nagler M; Hirzel C; Maurer B; Moor MB
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35361691
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic.
    Mravčík V; Husa P; Kumpanová Valachovičová S; Vobořil J
    Epidemiol Mikrobiol Imunol; 2022; 71(1):9-20. PubMed ID: 35477266
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients.
    Oyaert M; De Scheerder MA; Van Herrewege S; Laureys G; Van Assche S; Cambron M; Naesens L; Hoste L; Claes K; Haerynck F; Kerre T; Van Laecke S; Van Biesen W; Jacques P; Verhasselt B; Padalko E
    Front Immunol; 2022; 13():858399. PubMed ID: 35401575
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations.
    Meredith RT; Bermingham MD; Bentley K; Agah S; Aboagye-Odei A; Yarham RAR; Mills H; Shaikh M; Hoye N; Stanton RJ; Chadwick DR; Oliver MA
    Front Cell Infect Microbiol; 2023; 13():1207313. PubMed ID: 37424787
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
    Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
    Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
    Front Immunol; 2022; 13():834981. PubMed ID: 35154159
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
    Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
    Front Immunol; 2022; 13():981350. PubMed ID: 36059485
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
    Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF
    J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France.
    Graça D; Brglez V; Allouche J; Zorzi K; Fernandez C; Teisseyre M; Cremoni M; Benzaken S; Pradier C; Seitz-Polski B
    J Clin Immunol; 2023 Nov; 43(8):1724-1739. PubMed ID: 37606852
    [TBL] [Abstract][Full Text] [Related]  

  • 79. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals.
    Lozano-Rodríguez R; Avendaño-Ortíz J; Terrón V; Montalbán-Hernández K; Casalvilla-Dueñas J; Bergón-Gutiérrez M; Mata-Martínez P; Martín-Quirós A; García-Garrido MÁ; Del Balzo-Castillo Á; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; López-Morejón L; Vela-Olmo C; Cubillos-Zapata C; López-Collazo E; Del Fresno C
    Front Immunol; 2023; 14():1136029. PubMed ID: 37153580
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Monoclonal gammopathy of ocular significance (MGOS) - a short survey of corneal manifestations and treatment outcomes.
    Garderet L; Al Hariri M; Wasielica-Poslednik J; Munder M; Kormányos K; Pena C; Gozzetti A; Zhou X; Waszczuk-Gajda A; Rosinol L; Mikala G; Krzystanski M; Lisch W; Vesole D; Szentmáry N; Jurczyszyn A
    Leuk Lymphoma; 2022 Apr; 63(4):984-990. PubMed ID: 34823428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.